Zobrazeno 1 - 10
of 29
pro vyhledávání: '"James B. Moberly"'
Autor:
James B. Moberly, Shashank Rohatagi, Kenneth E. Truitt, Ching Hsu, Hamim Zahir, Robert J. Noveck
Publikováno v:
The Journal of Clinical Pharmacology. 52:996-1006
CS-0777 is a selective sphingosine 1-phosphate receptor-1 (S1P(1)) modulator under development for treatment of autoimmune conditions. A randomized, double-blind, placebo-controlled study was conducted to assess the safety, tolerability, pharmacokine
Autor:
Hamim Zahir, Kenneth E. Truitt, James B. Moberly, Timothy J. Carrothers, Takaichi Shimozato, Shashank Rohatagi, Shin-ichi Inaba
Publikováno v:
The Journal of Clinical Pharmacology. 49:50-62
Pharmacokinetic (PK) and exposure-response modeling of a selective sphingosine 1-phosphate receptor-1 modulator (CS-0777) was conducted in an iterative process to guide early clinical development decisions. A model based on preclinical data from monk
Autor:
K. Yoshihara, Daniel E. Salazar, Russ Wada, Y. Gao, James B. Moberly, Jianbo Xu, Shashank Rohatagi, Helen Kastrissios, N. Zhang, Kenneth E. Truitt, M. Takahashi
Publikováno v:
The Journal of Clinical Pharmacology. 47:358-370
The objectives of these analyses were to (1) develop a population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor (CS-706) using data from primarily Caucasian subjects, (2) predict responses in subpopulations of interest (including
Autor:
James B. Moberly, Dennis S. Riff, Yaping Wan, Tara Breese, Janet E. Lawson, Stuart I. Harris, Kenneth E. Truitt, Jianbo Xu, Patrick McLaughlin, James Craig Dale
Publikováno v:
Digestive Diseases and Sciences. 52:442-450
CS-706 is a novel cyclooxygenase-2 (COX-2) inhibitor with potent analgesic, anti-inflammatory, and antitumor properties in animal models. This one-week, multicenter study was undertaken to assess the safety and tolerability of CS-706 and to compare t
Autor:
Philip Mathew, James B. Moberly, J. F. Marier, Siva Rama Prasad Kambhampati, Daniel E. Salazar, James Lee, Rudolf Guilbaud
Publikováno v:
The Journal of Clinical Pharmacology. 46:310-320
AST-120 is an orally administered adsorbent used to slow the progression of chronic kidney disease (CKD). This was a randomized, open-label, 5-way crossover study to assess the effect of AST-120 on the pharmacokinetics of losartan and its active meta
Autor:
James B. Moberly, J. F. Marier, James Lee, Siva Rama Prasad Kambhampati, Daniel E. Salazar, Ramon Vargas, Lawrence Galitz
Publikováno v:
American Journal of Nephrology. 26:136-141
Background: AST-120 is an orally administered adsorbent used in Japan for prolonging time to initiation of hemodialysis and improving uremic symptoms in patients with chronic kidney disease (CKD). As AST-120 is suspected to reduce the progression of
Autor:
Andrzej Breborowicz, Leo Martis, Justyna Wisniewska, Alicja Polubinska, James B. Moberly, Katarzyna Wieczorowska-Tobis, Dimitrios G. Oreopoulos, Katarzyna Korybalska
Publikováno v:
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 22:293-300
ObjectiveL-2-Oxothiazolidine-4-carboxylate (OTZ), a cysteine precursor, is a substrate for intracellular glutathione synthesis. As shown previously, OTZ prevents free-radical induced cellular damage during in vitro simulation of peritoneal dialysis.
Autor:
Chi Chen, Andrzej Breçborowicz, Krzystof Pawlaczyk, Alicja Polubinska, James B. Moberly, Leo Martis, Malgorzata Kuzlan-Pawlaczyk, Katarzyna Wieczorowska-Tobis, Dimitrios G. Oreopoulos
Publikováno v:
Kidney International. 57(3):1182-1189
Dialysis solution containing hyaluronan: Effect on peritoneal permeability and inflammation in rats.BackgroundHyaluronan (HA), a high molecular weight mucopolysaccharide found in interstitial tissues and fluid, is lost from the peritoneal cavity duri
Publikováno v:
American Journal of Kidney Diseases. 30:489-494
Dialysis patients are reported to have impaired antioxidant mechanisms, including those involving glutathione-dependent enzymes. This study used high-performance liquid chromatography assays that directly measure total (oxidized + reduced) glutathion
Autor:
Marco Pappagallo, Brenda Breuer, Christopher Noto, James B. Moberly, Paolo L Manfredi, Angela Sanchez, Hung-Mo Lin, Julia Tai
Publikováno v:
Pain. 155(1)
Intravenous (i.v.) bisphosphonates relieve pain in conditions such as Paget's disease of bone, metastatic bone disease, and multiple myeloma. Based on positive findings from a prior case series, we conducted a randomized placebo-controlled study to a